logo
  

Adamis Says Clinical Trial Start-up Activities Underway For Tempol In Treatment Of COVID-19

Adamis Pharmaceuticals Corp. (ADMP) said Friday that clinical trial start-up activities are underway for examining the effects of its experimental drug, Tempol, in the treatment of COVID-19. The company is carrying out the activities with a large clinical research organization.

In Friday pre-market trade, ADMP was trading at $1.10 up $0.08 or 7.84%.

The commenced activities include site identification and initiation, data base production, vendor management, and the establishment of an independent data safety monitoring board of infectious disease experts, who will review the safety and efficacy of the trial.

The goal of the trial is to examine the safety and activity of Tempol in COVID-19 patients early in the infection. The trial is entitled "A Phase 2/3, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effects of Tempol (MBM-02) on Preventing COVID-19 Related Hospitalization in Subjects with COVID-19 Infection.

Tempol produced a 5 log decrease in virus levels in cells infected with SARS-CoV-2. Tempol performed better in inhibiting RNA replicase than Remdesivir, which has been approved on an emergency use basis for the treatment of COVID-19. Tempol also synergized with Remdesivir.

Adamis has a worldwide license to use Tempol for the treatment of respiratory diseases including asthma, respiratory syncytial virus, influenza and COVID-19.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Longmont Colorado -based Royal Crest Dairy is recalling 2% Chocolate Milk citing the potential to be contaminated with undeclared egg, a known allergen, the U.S. Food and Drug Administration said. The recall involves Farmer's 2% Reduced Fat Chocolate Milk Pints with the code date of AUG-22. ANI Pharmaceuticals, Inc. (ANIP) Monday announced a wider loss for the second quarter, despite a 52 percent surge in revenues. For the full year 2022, the company reiterated the adjusted earnings per share range, revenue guidance and raised Cortrophin revenue outlook. The company reported a quarterly... Shares of BioNTech SE were losing around 4 percent in the morning trading in Germany and around 5 percent in the pre-market activity on Nasdaq after the German Covid-19 vaccine maker reported sharp drop in profit and revenues for the second quarter. However, the company recorded strong growth in first-half results. Further, the company maintained BioNTech COVID-19 vaccine revenue guidance
Follow RTT